Mersana Therapeutics Inc (MRSN) concluded trading on Thursday at a closing price of $0.38, with 6.37 million shares of worth about $2.42 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -72.06% during that period and on July 10, 2025 the price saw a gain of about 12.69%. Currently the company’s common shares owned by public are about 124.63M shares, out of which, 96.84M shares are available for trading.
Stock saw a price change of 35.86% in past 5 days and over the past one month there was a price change of -2.76%. Year-to-date (YTD), MRSN shares are showing a performance of -79.79% which decreased to -73.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $2.83 during that period. The average intraday trading volume for Mersana Therapeutics Inc shares is 2.82 million. The stock is currently trading 13.30% above its 20-day simple moving average (SMA20), while that difference is up 7.62% for SMA50 and it goes to -63.25% lower than SMA200.
Mersana Therapeutics Inc (NASDAQ: MRSN) currently have 124.63M outstanding shares and institutions hold larger chunk of about 50.03% of that.
The stock has a current market capitalization of $47.36M and its 3Y-monthly beta is at 0.83. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 1.83. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRSN, volatility over the week remained 8.35% while standing at 9.44% over the month.
Analysts are in expectations that Mersana Therapeutics Inc (MRSN) stock would likely to be making an EPS of -0.17 in the current quarter, while forecast for next quarter EPS is -0.15 and it is -0.64 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.21 which is -0.08 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -6.99% while it is estimated to increase by 2.50% in next year. EPS is likely to shrink at an annualized rate of -8.65% for next 5-years, compared to annual growth of 2.74% made by the stock over the past 5-years.
Coverage by Citigroup stated Mersana Therapeutics Inc (MRSN) stock as a Buy in their note to investors on November 15, 2024, suggesting a price target of $5 for the stock. On March 19, 2024, JP Morgan Upgrade their recommendations, while on February 29, 2024, Wedbush Upgrade their ratings for the stock with a price target of $7. Stock get a Buy rating from Guggenheim on February 29, 2024.
